ST Avecilla, K Hattori, B Heissig, R Tejada, F … - Nature medicine, 2004 - tufts.edu The precise mechanism by which hematopoietic progenitor cells differ- entiate,
proliferate, mature and enter the circulation is not known. Cytokines, including
TPO, support hematopoiesis primarily by promot- ing proliferation of ... Cited by 259 - Related articles - BL Direct - All 5 versions
- ►bloodjournal.org J Li, C Yang, Y Xia, A Bertino, J Glaspy, M … - Blood, 2001 - Am Soc Hematology In these clinical studies, both recombinant TPOs were safe and not associated
with thrombosis. However, PEG-rHuMGDF was paradoxically associated with the
development of persistent thrombocytopenia (platelet count 100 × 10 9 /L) ... Cited by 222 - Related articles - BL Direct - All 4 versions
- ►hematologylibrary.org - Free from Publisher DJ Kuter, CG Begley - Blood, 2002 - bloodjournal.hematologylibrary.org Thrombocytopenia is a common problem in the management of patients with cancer
and other conditions that affect hematopoietic cells. Thrombocytopenia may be
occasionally encountered with conventional chemotherapy regimens used to ... Cited by 149 - Related articles - BL Direct - All 7 versions
K Kaushansky - 新英格兰医药杂志, 2006 - journal.shouxi.net In 1906, Carnot1 found that injecting healthy rabbits with serum from anemic
animals prompted a rapid increase of erythrocytes in the recipients. The
responsible humoral substance was first termed "hemopoietine" and was later ... Cited by 115 - Related articles - Cached - BL Direct - All 6 versions
- ►hematologylibrary.org DJ Kuter - Clinical Lymphoma & Myeloma, 2009 - CIG Media Group Introduction Thrombopoietin (TPO) receptor mimetics are now available for the
treatment of some forms of thrombocytopenia. Although first proposed to exist in
1958,1 almost 40 years of arduous investiga- tion passed before TPO was ... Cited by 94 - Related articles - BL Direct - All 7 versions
- ►bloodjournal.org LT Goodnough, DJ Kuter, J McCullough, SJ … - Blood, 2001 - Am Soc Hematology Although hematopoietic growth factors were initially administered only to
patients, these growth factors have been administered recently to healthy donors
who have become an important resource for transfusion medicine support in ... Cited by 48 - Related articles - BL Direct - All 4 versions
- ►bloodjournal.org DJ Kuter, LT Goodnough, J Romo, J DiPersio, … - Blood, 2001 - Am Soc Hematology Platelet transfusions are essential to prevent morbidity and mortality in
patients who are severely thrombocytopenic. Platelets for transfusion are
currently obtained either by fractionation of whole blood or by platelet ... Cited by 43 - Related articles - BL Direct - All 4 versions
- ►thelancet.com S Vadhan-Raj, JJ Kavanagh, RS Freedman, J … - The Lancet, 2002 - Elsevier 20 patients with gynaecological malignancies were treated with two doses of 1·2
μg/kg recombinant human thrombopoietin. From day 12, we aimed to collect 50
units of platelets from these patients by plateletpheresis. Harvested ... Cited by 40 - Related articles - All 7 versions
- ►hematologylibrary.org - Free from Publisher T Orita, H Tsunoda, N Yabuta, K Nakano, T … - Blood, 2005 - bloodjournal.hematologylibrary.org Antibodies have brought valuable therapeutics in the clinical treatment of
various diseases without serious adverse effects through their intrinsic
features such as specific binding to the target antigen with high affinity, ... Cited by 36 - Related articles - All 5 versions
- ►alphamedpress.org GD Demetri - The Oncologist, 2001 - AlphaMed Press Molecular targeting of novel therapies has the promise of inducing very specific
biologic effects. In clinical hematology and oncology, molecular targeting of
specific cell surface receptors with erythropoietin, G-CSF, or GM-CSF has ... Cited by 33 - Related articles - BL Direct - All 12 versions
